scholarly journals Quantitative CT imaging features correlate with colorectal cancer liver metastases (CLM) mutational status

HPB ◽  
2018 ◽  
Vol 20 ◽  
pp. S56-S57
Author(s):  
R.M. Marcus ◽  
D.T. Fuentes ◽  
H.A. Lillemoe ◽  
A. Qayyum ◽  
T.A. Aloia
2020 ◽  
Vol 45 (4) ◽  
pp. 1075-1081
Author(s):  
Wujian Mao ◽  
Jun Zhou ◽  
Lin Qiu ◽  
Hongyan Yin ◽  
Hui Tan ◽  
...  

2022 ◽  
Vol 11 ◽  
Author(s):  
Yun Wang ◽  
Lu-Yao Ma ◽  
Xiao-Ping Yin ◽  
Bu-Lang Gao

Colorectal cancer is one common digestive malignancy, and the most common approach of blood metastasis of colorectal cancer is through the portal vein system to the liver. Early detection and treatment of liver metastasis is the key to improving the prognosis of the patients. Radiomics and radiogenomics use non-invasive methods to evaluate the biological properties of tumors by deeply mining the texture features of images and quantifying the heterogeneity of metastatic tumors. Radiomics and radiogenomics have been applied widely in the detection, treatment, and prognostic evaluation of colorectal cancer liver metastases. Based on the imaging features of the liver, this paper reviews the current application of radiomics and radiogenomics in the diagnosis, treatment, monitor of disease progression, and prognosis of patients with colorectal cancer liver metastases.


2021 ◽  
pp. HEP40
Author(s):  
Giammaria Fiorentini ◽  
Donatella Sarti ◽  
Michele Nardella ◽  
Riccardo Inchingolo ◽  
Massimiliano Nestola ◽  
...  

Aims: Bevacizumab (B) in association with systemic chemotherapy is commonly used for the treatment of colorectal cancer liver metastases. The aim of this study was to monitor tumor response, overall survival (OS) and progression-free survival (PFS) of patients with colorectal cancer liver metastases treated with transarterial chemoembolization (TACE) + B compared with TACE alone and to correlate the results with KRAS mutational status. Patients & methods: This was an observational multicentric case–control study (NCT03732235) on the efficacy and safety of B administered after TACE. Results: The disease control rate was significantly higher for the TACE + B than the TACE alone group (p < 0.001). KRAS wild-type patients had a significantly better disease control rate than those with KRAS mutations in the TACE + B group. Median OS and PFS were similar for the TACE + B and TACE groups, whereas median time to progression was significantly higher for the TACE + B group (p < 0.01). Conclusion: The combination of TACE with B may improve tumor response and delay disease progression.


Sign in / Sign up

Export Citation Format

Share Document